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INTRODUCTION
Acinic cell carcinoma (AciCC) is a relatively uncommon malig-
nancy accounting for 1 to 6% of all salivary gland tumors and 
15% of all malignant tumors in parotid gland (1, 2). Interesting-
ly, AciCC was originally described as an adenoma, but from the 
1950s the term acinic cell adenocarcinoma was coined when its 
ability to metastasize and recur locally had been recognized (3, 
4). It is hard to diagnose AciCC of parotid gland preoperatively. 
Computed tomography (CT) scan demonstrated a low sensitivi-
ty rate for malignancy. The yield of fine needle aspiration cytol-
ogy (FNAC) was not high enough to make a correct prediction 
for AciCC (5). The results of AciCC treatment are quite variable. 
Local recurrence rate has been reported in 8 to 56% of the pa-
tients (5). Mortality from the disease is usually less than 10% at 
5 years (6).
  Because AciCC is rare and was recently recognized as the en-
tity of malignancy, AciCC has been difficult to study. In this study, 
we retrospectively reviewed 20 parotid AciCC patients undergo-
ing surgery from 1990 to 2009. We aimed to analyze the diagno-
sis and treatment experience for this malignancy in our hospital.
MATERIALS AND METHODS
We retrospectively reviewed the charts of 20 patients diagnosed 
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as parotid AciCC in the Department of Otorhinolaryngology at 
the Seoul National University Hospital from 1990 to 2009. It 
was conducted with the approval of institutional review board 
of SNUH. All patients received surgical intervention with a diag-
nosis of tumor of the parotid gland, which was confirmed patho-
logically. The records were analyzed for age, sex, clinical features, 
duration of symptoms, facial palsy, FNAC, imaging study (CT 
scan), intraoperative frozen section examination, treatment mo-
dalities, histopathologic findings, survival, recurrence. The stag-
ing system was based on the 7th American Joint Committee on 
Cancer staging criteria (7). Postoperative radiotherapy (RT) was 
performed on patients with advanced tumor stage or lack of 
confidence as to safety surgical margins. Chemotherapy was 
performed on one patient with distant metastasis.
  SPSS ver. 18.0 (SPSS Inc., Chicago, IL, USA) was used for 
statistical analysis. Overall cumulative survival rate and disease 
free survival rate was calculated with Kaplan-Meier method.
RESULTS
Demographics and symptoms
This study comprised 20 patients diagnosed as parotid AciCC. 
There were 10 males and 10 females, with a mean age of 44.4 
years (range, 8 to 77 years). No significant gender predominance 
was found in this study. Mean follow-up duration was 111 months 
(range, 17 to 251 months). Tumors were mainly located in the 
superficial lobe (12 cases, 60%), while there were 8 (40%) in 
deep lobe. Among all patients, infra-auricular mass was the most 
common initial presentation (95%). There was no patient that 
complained facial palsy preoperatively. 
Fine needle aspiration and CT findings
CT scans were performed in all patients. The radiologists in charge 
of interpretation of CT scan reported following four statements 
- benign mass lesion (8 cases, 40%), more possible benign lesion 
(5 cases, 25%), more possible malignancy (1 cases, 5%), and 
malignancy (6 cases, 30%).
  Fifteen patients had preoperative FNAC. Four cases (26.7%) 
had a cytology diagnosis that was consistent with AciCC. Instead 
of a correct diagnosis, suspected neoplasm (5 cases, 33.3%), be-
nign (2 cases, 13.3%), atypical cell (2 cases, 13.3%), pleomor-
phic adenoma (1 case, 6.7%) and Warthin’s tumor (1 case, 6.7%) 
were reported. Intraoperative frozen section were examined in 
16 patients, which offered 8 (50%) diagnoses that were consis-
tent with AciCC (Table 1).
Surgical treatment modality
All patients underwent surgical intervention of parotid gland tu-
mor. Twelve patients underwent superficial parotidectomy and 8 
had total parotidectomy. Facial nerve dissection and preserva-
tion were accomplished in 14 patients. In 6 patients, facial nerve 
was sacrificed without reconstruction due to advanced stage or 
tumor involvement. One patient underwent sural nerve graft re-
construction after facial nerve resection at the same operation. 
One patient with level II lymph node involvement and lung me-
tastasis underwent superficial parotidectomy, ipsilateral radical 
neck dissection and lung lobectomy (Table 2).
Pathologic staging
The T staging was summarized as follows: T1 in 5 (20%) patients, 
T2 in 9 (45%) patients, T3 in 4 (20%) patients, and T4 in 2 (10%) 
patients. One patient had cervical lymph node involvement and 
lung metastasis (Table 3). The AJCC tumor stage distributions of 
the patients were 14 (70%), 3 (15%), and 3 (15%) for stages I, 
II, and IV, respectively. 
Radiotherapy and chemotheapy
After surgery of parotid AciCC, postoperative radiotherapy was 
given in 8 patients, and adjuvant concurrent chemoradiotherapy 
was used in 1 patient. 
Table 1. The results of fine needle aspiration cytology and intraoper-
ative frozen section 
Status No. (%)
Fine needle aspiration cytology                       15
Acinic cell carcinoma 4 (26.7)
Suspected neoplasm 5 (33.3)
Benign 2 (13.3)
Atypical cell 2 (13.3)
Pleomorphic adenoma 1 (6.7)
Warthin’s tumor 1 (6.7)
Intraoperative frozen section                        16
Acinic cell carcinoma 8 (50.0)
Benign 5 (31.3)
Mucoepidermoid carcinoma 2 (12.5)
Malignancy 1 (6.3)
Table 2. Surgical treatment and facial nerve involvement 
Variables No. (%)
Surgical treatment 
Superficial parotidectomy  12 (60.0)
Total parotidectomy  8 (40.0)
Facial nerve 
Preservation  14 (70.0)
Sacrifice  6 (30.0)
Table 3. Pathologic TNM stage in parotid acinic cell carcinoma 
N0 N1 N2 N3 Total
T1   5 0 0 0   5
T2   9 0 0 0   9
T3   3 0  1* 0   4
T4   2 0 0 0   2
Total 19 0 1 0 20
*Level II lymph node involvement and lung metastasis (M1).190    Clinical and Experimental Otorhinolaryngology   Vol. 4, No. 4: 188-192, December 2011
Treatment outcome, recurrence and prognosis
 There are 5 cases of recurrence after surgery with or without 
adjuvant treatment. Three cases of distant metastasis occured. 
Among them, 2 patients developed lung and one brain metasta-
sis were in 2 and 1 respectively. Two patients had local recurrence 
in tumor bed. Overall stage was correlated with recurrence. How-
ever, there is no significant relationship with tumor size, tumor 
location, resection margin and lymphovascular invasion (Table 
4). One patient initially was diagnosed with lung metastasis died 
of brain metastasis after the operation and concurrent chemora-
diotherapy. 
  The 10-year cumulative survival rate was 90.9% with a mean 
follow-up of 111 months, ranging 17-251 months. The 10-year 
disease free survival rate was 74.2% and the mean duration of 
recurrence from initial surgery was 92.3 months (Fig. 1).
DISCUSSION
Demographics and symptoms
AciCC is a rare malignancy. It was initially thought to be benign 
disease entity and Foote and Frazell (3) first coined it as a carci-
noma in the early 1950s. Its ability to metastasize and recur lo-
cally was first reported. Because of its rarity, initial misunder-
standing and unknown character of AciCC, it has been difficult 
to study (8). 
  Patients usually visit doctors with the symptom of incidental 
infra-auricular mass. Facial palsy or pain usually may not exist 
at the first time. In other studies, the tumor usually appeared as 
a painless mass in either the superficial or deep lobe of the pa-
rotid gland (9-13). In our study, most of the patients visited for 
infra-auricular mass and there was no patient that complained 
facial palsy preoperatively. It was thought that the slow growth 
pattern of AciCC made the mass painless.
  In the literature, the female-to-male ratio is about 1.5:1, and 
the tumor usually occurs in the fifth and sixth decades of life 
(14). Most of studies have shown females predominant to males 
at a higher rate. Exceptionally Ellis and Corio (12) suggested 
that 155 of 294 patients were male (53%). In our study, there 
was no predominance of gender. A mean age of 44.4 years at di-
agnosis in our study was younger than that found in past ones. 
Fine needle aspiration and CT findings
Preoperative imaging studies are widely used for head and neck 
tumors. In our study, CT scan demonstrated a low sensitivity 
rate for malignancy like FNAC. Six cases were suspected with 
malignancy preoperatively by CT scan. There was no unique 
characteristic of parotid gland AciCC in the CT scan. Fine nee-
dle aspiration cytology could help clinicians in the differential 
diagnosis of parotid malignancy from other benign tumors. As 
for AciCC of parotid gland, the diagnostic ability of FNAC is not 
good. In other study, 12 patients had preoperative fine-needle 
aspiration, while only two cases (17%) were consistent with cor-
rect cytology diagnosis for AciCC (5). From our experience, the 
yield of FNAC (4 of 15 cases, 26.7%) was not high enough to 
make a correct diagnosis of AciCC preoperatively. An adjuvant 
diagnostic tool for diagnosis of parotid AciCC was necessary, so 
we performed intraoperative frozen section biopsy and exami-
nation. In our result, the sensitivity of intraoperative frozen sec-
tion itself was 50% and when performed simultaneously with 
FNAC, its sensitivity was 69.2%. 
Table 4. Relationships between pathological parameters and recur-
rence 
Parameter 
Recurrence
P-value
Yes No
Stage
I 1 (7.1) 13 (92.9) 0.003
II 1 (33.3) 2 (66.7)
III 0 (0) 0 (0)
IV 3 (100.0) 0 (0)
Tumor size
<3 3 (30.0) 7 (70.0) 1.000
≥3 2 (20.0) 8 (80.0)
Tumor location
Superficial lobe 3 (25.0) 9 (75.0) 1.000
Deep lobe 2 (25.0) 6 (75.0)
Resection margin
Positive 0 (0) 6 (100.0) 0.260
Negative 5 (35.7) 9 (64.3)
Lymphovascular invasion
Yes 1 (33.3) 2 (66.7) 1.000
No 4 (23.5) 13 (76.5)
Fig. 1. 10-year disease free survival of parotid acinic cell carcinoma 
patients.
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Surgical treatment modality
The surgical treatment of choice is total or superficial parotidec-
tomy with dissection of the facial nerve according to mass loca-
tion. Facial nerve preservation was intra-operatively attempted 
in all patients except those with macroscopic nerve involvement. 
If the tumor was well encapsulated without extra-capsular spread, 
Gomez et al. (15) suggested that surgery alone was satisfactory 
in the control of AciCC. Positive surgical margin was regarded as 
an important prognostic factor in AciCC (15). However, from 
our analysis, there was no recurrence in all cases with positive 
resection margin. 
Pathologic staging
AciCC is considered a low-grade salivary gland carcinoma with 
low rate of recurrence and metastasis, and is generally thought 
to carry a good prognosis. It usually presents as a single or mul-
tilobular mass. Cystic degeneration or hemorrhage may be seen 
in histopathology. The neoplastic cells have morphologic similar-
ity with the normal acinic cells. The pathological diagnosis of 
AciCC depends on identifying cells presenting serous acinar cell 
differentiation (Fig. 2). 
  Immunohistochemical staining of AciCC is not specific and 
does not play an important role in diagnosis. Neural, vessel, or 
stromal invasion is rare and regarded as a poor prognostic factor 
(15). Gomez et al. (15) reported that high-grade AciCC with the 
features of tumor necrosis and high mitotic figures were corre-
lated with poor disease free survival. But the information of 
nerve involvement, stromal invasion, high mitotic figures and 
tumor necrosis were not mentioned in our pathologic report. 
  The cervical lymph node metastatic rate in AciCC was report-
ed to be 2.86% with N1 and 5.71% with N2b lesions and the 
rate of occult regional metastasis was low (15). In our study, re-
gional metastasis in level IIb was found in one patient (1 of 20 
patients, 5%). To date, the role of neck dissection in AciCC re-
mains controversial. Therapeutic neck dissection is the accepted 
treatment for patients with clinically obvious cervical nodal in-
volvement. However, the elective neck dissection of the clinical-
ly negative neck is not well defined in the published work. The 
role of elective neck dissection was not evident in our study or 
in other studies (15). Some authors suggest routine elective neck 
dissection in all N0 parotid carcinomas regardless of histology 
(16). Stennart et al. (17) also recommended a similar treatment, 
because most salivary gland malignancy including AciCC are 
not radiosensitive. However, no survival gain has been shown in 
these two studies. In contrast, several other authors do not be-
lieve that routine neck dissection is recommended (6, 12, 18, 
19). In our study, we did not perform elective neck dissection on 
the clinically negative neck and there was no regional treatment 
failure. In one case of cervical lymph node involvement with 
lung metastasis, we performed the ipsilateral radical neck dis-
section along with superficial parotidectomy and lung lobecto-
my for oncologic safety.
Radiotherapy and chemotherapy
There has been no prospective randomized study to evaluate 
the effectiveness of radiotherapy. Primary radiotherapy should 
be restricted to patients not suitable for surgery or refusing sur-
gery because AciCC has generally not been regarded as being 
radiosensitive. Some authors have only found a limited response 
(18, 20). Others have claimed a response to postoperative radio-
therapy (9, 21). Spafford et al. (9) proposed a series of indica-
tions for postoperative adjunctive radiotherapy in AciCC: 1) re-
current tumor; 2) equivocal or positive margins, or evidence of 
tumor spillage; 3) tumor adjacent to the facial nerve; 4) deep-
lobe involvement; 5) lymph node metastases; 6) extra-parotid 
extension; and 7) large tumors greater than 4 cm. Greig et al. 
(22) suggested that the indications for postoperative radiothera-
py used were the presence of high-grade histological features 
(evidence of lympho-vascular invasion and high mitotic rate), 
close or positive margins at initial resection and tumor recur-
rence.
  In our study, patients with advanced stage or positive resec-
tion margin were given adjuvant postoperative radiotherapy and 
had good tumor control. We recommend giving adjuvant radia-
tion therapy in these high-risk patients. There are few studies 
about the effectiveness of chemotherapy in parotid AciCC. In 
our study, we adopted chemotherapy as adjuvant therapy in one 
patient with lung metastasis but after several recurrences, the 
patient died of brain metastasis. We could not evaluate the out-
come of chemotherapy due to limited cases in this study.
Treatment outcome and prognosis
It was reported that local recurrence rates ranged from 0 to 44%. 
Reported cervical nodal metastases have ranged from 0% to 
43%. Distant metastases have ranged from 0 to 13% (1, 9, 12, 
Fig. 2. Histology showing a section of the acinic cell carcinoma tis-
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18-20, 23). In our study, local recurrence rate and distant metas-
tases were 10% and 15%. There was no regional recurrence af-
ter treatment. The cases of distant metastasis had more aggres-
sive clinical feature than others. They were suspicious for high 
grade AciCC but we could not found the pathologic reports about 
tumor necrosis and high mitotic figures.
  AciCC had better prognosis relative to other malignancies, 
with 10- and 20-year survivals of 88% and 83%, respectively in 
the literature (24). The prognosis of AciCC is variable from many 
series studies, ranging from 55 to 89% (15, 20, 21). Eneroth et al. 
(21) reported that the cure rate decreased from 89% at 5 years 
to 56% at 20 years. Spiro et al. (20) reported the survival rate to 
be 76% at 5 years, 63% at 10 years, and 55% at 15 years. Ac-
cording to our data, prognosis was good, and the 10-year dis-
ease free survival rate was 74.2% and the overall 10-year sur-
vival rate was 90.9%. 
  AciCC has been noted to recur many years after initial diag-
nosis and surgery. Spiro (25) reported two cases recurring be-
yond 30 years of follow-up, a median time to recurrence of 3 
years, and median time to death from disease of 10 years. How-
ever, the large study of 294 patients by Ellis and Corio (12) 
showed that 82% of first recurrences and metastases occurred 
within 5 years of initial therapy. Two patients recurred after 11 
and 13 years respectively in our patients. Other authors have 
maintained that a follow-up of at least 20 years is necessary to 
adequately determine final treatment outcomes (9, 26). 
  In conclusions, parotid AciCC is a rare malignancy that has 
features of less aggressive behavior, and good prognosis. Intra-
operative frozen section examination may be helpful in the di-
agnosis of parotid AciCC because of the low sensitivity of pre-
operative CT scan and FNAC. Surgery with adjuvant postopera-
tive radiotherapy is satisfactory for disease control. 
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